SENIOR SECURED CONVERTIBLE PROMISSORY NOTE DUE July 7, 2018Immune Pharmaceuticals Inc • July 10th, 2017 • Pharmaceutical preparations • New York
THIS SENIOR SECURED CONVERTIBLE PROMISSORY NOTE is one of a series of duly authorized and validly issued Senior Secured Convertible Notes of Immune Pharmaceuticals, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ 07632, designated as its Senior Secured Convertible Promissory Note due July 7, 2018 (this “Note”, or the “Note” and collectively with the other Notes of such series, the “Notes”).
EXCHANGE AGREEMENTExchange Agreement • July 10th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS EXCHANGE AGREEMENT (the “Agreement”) is dated this 7th day of July, 2017 (the “Effective Date”), by and among Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and MEF I, L.P. (the “Holder”).
ASSIGNMENT AGREEMENTAssignment Agreement • July 10th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • California
This Assignment Agreement (the “Assignment Agreement”) is dated as of July 7, 2017 (the “Effective Date”) by and among Immune Pharmaceuticals, Inc., a Delaware corporation (“IMNP”), Immune Pharmaceuticals USA Corp. (“IMNP USA”; and together with IMNP and each of their respective subsidiaries, “Borrower”), MEF I, L.P. (“Assignee”), and Hercules Capital, Inc. (f/k/a, Hercules Technology Growth Capital, Inc.), a Maryland corporation (“Hercules”).
